## **Prior Authorization Form Synagis® (palivizumab)**

Today's date	Date medication needed	
•		



	D REQUESTS WILL BE REVIEWED	
Patient information (please print)		
	Subscriber name	
Address	City, state, ZIP	
Telephone # Member	D # Date of birth	
Does the patient have any allergies?  Yes N Previous Synagis® (palivizumab) injections? (includin	g doses given in NICU)  Expected date of next injection	
Physician information (please print)		
	Prescriber NPI	
Office address	City, state, ZIP	
	Telephone # Fax #	
Diagnosis and patient history (check all tl  ☐ Breakthrough RSV hospitalization during the cl ☐ Chronic lung disease of prematurity (specify logation as Does patient have chronic lung disease of prematurity as Does patient receiving medical treatment? (check ☐ Oxygen (dates) ☐ ☐ ☐ Congenital heart disease (CHD) (specify ICD-9	urrent RSV season  CD-9 code; then complete a – b below)  onary consults.  naturity?  I Yes No  all that apply below and provide dates)  Corticosteroids (dates)  Bronchodilator (dates)	
Attach supporting documentation, including latest cardiology consults and echocardiograms/catheterization record  a. Diagnosis of hemodynamically significant acyanotic CHD?  b. Diagnosis of hemodynamically significant cyanotic CHD?  c. Consultation with pediatric cardiologist regarding use of Synagis® (palivizumab)?  d. List of medications currently used to control congestive heart failure  Prematurity (gestational age 28 weeks, 6 days or younger)		
<ul> <li>Severe neuromuscular disease or congenital a respiratory secretions (specify ICD-9 code)</li> </ul>	bnormalities of the airway that compromise mobilization of	
Prescription information  Synagis® (palivizumab): 50 mg and/or 100 mg vialusing: Reconstitute as directed and give 15 mg/kg intransplayed in the Dispense quantity Refill xmonth.  Physician's signature	nuscular injection once per month n(s)	

AmeriHealth Insurance Company of New Jersey | AmeriHealth HMO, Inc | QCC Insurance Company, d/b/a AmeriHealth Insurance Company